Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis.

Estill, Janne; Venkova-Marchevska, Plamenna; Günthard, Huldrych F; Botero-Mesa, Sara; Thiabaud, Amaury; Roelens, Maroussia; Vancauwenberghe, Laure; Damonti, Lauro; Heininger, Ulrich; Iten, Anne; Schreiber, Peter W; Sommerstein, Rami; Tschudin-Sutter, Sarah; Troillet, Nicolas; Vuichard-Gysin, Danielle; Widmer, Andreas; Hothorn, Torsten; Keiser, Olivia (2023). Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis. Swiss medical weekly, 153(8), pp. 1-11. SMW supporting association 10.57187/smw.2023.40095

Preview

Text smw-2023-40095.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (3MB) | Preview

AIMS OF THE STUDY

Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by patient characteristics.

METHODS

We analysed data collected from a hospital surveillance study conducted in 21 referral hospitals in Switzerland between 2020 and 2022. We applied model-based recursive partitioning to group patients by the association between treatment levels and mortality. We included either treatment (levels: none, remdesivir within 7 days of symptom onset, remdesivir after 7 days, or another treatment), age and sex, or treatment only as regression variables. Candidate partitioning variables included a range of risk factors and comorbidities (and age and sex unless included in regression). We repeated the analyses using local centring to correct the results for the propensity to receive treatment.

RESULTS

Overall (n = 21,790 patients), remdesivir within 7 days was associated with increased mortality (adjusted hazard ratios 1.28-1.54 versus no treatment). The CURB-65 score caused the most instability in the regression parameters of the model. When adjusted for age and sex, patients receiving remdesivir within 7 days of onset had higher mortality than those not treated in all identified eight patient groups. When age and sex were included as partitioning variables instead, the number of groups increased to 19-20; in five to six of those branches, mortality was lower among patients who received early remdesivir. Factors determining the groups where remdesivir was potentially beneficial included the presence of oncological comorbidities, male sex, and high age.

CONCLUSIONS

Some subgroups of patients, such as individuals with oncological comorbidities or elderly males, may benefit from remdesivir.

Interest & Impact

Downloads

30 since deposited on 03 Oct 2023
30 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item